» Articles » PMID: 27827408

Meta-analysis of Brain Iron Levels of Parkinson's Disease Patients Determined by Postmortem and MRI Measurements

Overview
Journal Sci Rep
Specialty Science
Date 2016 Nov 10
PMID 27827408
Citations 104
Authors
Affiliations
Soon will be listed here.
Abstract

Brain iron levels in patients of Parkinson's disease (PD) are usually measured in postmortem samples or by MRI imaging including R2* and SWI. In this study we performed a meta-analysis to understand PD-associated iron changes in various brain regions, and to evaluate the accuracy of MRI detections comparing with postmortem results. Databases including Medline, Web of Science, CENTRAL and Embase were searched up to 19 November 2015. Ten brain regions were identified for analysis based on data extracted from thirty-three-articles. An increase in iron levels in substantia nigra of PD patients by postmortem, R2* or SWI measurements was observed. The postmortem and SWI measurements also suggested significant iron accumulation in putamen. Increased iron deposition was found in red nucleus as determined by both R2* and SWI, whereas no data were available in postmortem samples. Based on SWI, iron levels were increased significantly in the nucleus caudatus and globus pallidus. Of note, the analysis might be biased towards advanced disease and that the precise stage at which regions become involved could not be ascertained. Our analysis provides an overview of iron deposition in multiple brain regions of PD patients, and a comparison of outcomes from different methods detecting levels of iron.

Citing Articles

Role of iron in brain development, aging, and neurodegenerative diseases.

Gao Q, Zhou Y, Chen Y, Hu W, Jin W, Zhou C Ann Med. 2025; 57(1):2472871.

PMID: 40038870 PMC: 11884104. DOI: 10.1080/07853890.2025.2472871.


The causal effects of gut microbiota on quantitative susceptibility mapping (QSM) and T2* imaging-derived phenotypes: insights from a Mendelian randomization study.

Huang B, Yang L, Liu F, Gou S, Liu J Quant Imaging Med Surg. 2024; 14(12):9220-9233.

PMID: 39698716 PMC: 11652028. DOI: 10.21037/qims-24-318.


Hemochromatosis neural archetype reveals iron disruption in motor circuits.

Loughnan R, Ahern J, Boyle M, Jernigan T, Hagler Jr D, Iversen J Sci Adv. 2024; 10(47):eadp4431.

PMID: 39576859 PMC: 11584016. DOI: 10.1126/sciadv.adp4431.


Abdominal multi-organ iron content and the risk of Parkinson's disease: a Mendelian randomization study.

Yang M, Tang C, Peng F, Luo C, Chen G, Kong R Front Aging Neurosci. 2024; 16:1416014.

PMID: 39206119 PMC: 11349543. DOI: 10.3389/fnagi.2024.1416014.


The Effects of Fisetin and Curcumin on Oxidative Damage Caused by Transition Metals in Neurodegenerative Diseases.

Bjorklund G, Oliinyk P, Khavrona O, Lozynska I, Lysiuk R, Darmohray R Mol Neurobiol. 2024; 62(1):1225-1246.

PMID: 38970766 DOI: 10.1007/s12035-024-04321-2.


References
1.
Biasiotto G, Di Lorenzo D, Archetti S, Zanella I . Iron and Neurodegeneration: Is Ferritinophagy the Link?. Mol Neurobiol. 2015; 53(8):5542-74. DOI: 10.1007/s12035-015-9473-y. View

2.
Wolozin B, Golts N . Iron and Parkinson's disease. Neuroscientist. 2002; 8(1):22-32. DOI: 10.1177/107385840200800107. View

3.
Kish S, Shannak K, Hornykiewicz O . Uneven pattern of dopamine loss in the striatum of patients with idiopathic Parkinson's disease. Pathophysiologic and clinical implications. N Engl J Med. 1988; 318(14):876-80. DOI: 10.1056/NEJM198804073181402. View

4.
Dexter D, WELLS F, Lees A, Agid F, Agid Y, Jenner P . Increased nigral iron content and alterations in other metal ions occurring in brain in Parkinson's disease. J Neurochem. 1989; 52(6):1830-6. DOI: 10.1111/j.1471-4159.1989.tb07264.x. View

5.
Ordidge R, Gorell J, Deniau J, Knight R, Helpern J . Assessment of relative brain iron concentrations using T2-weighted and T2*-weighted MRI at 3 Tesla. Magn Reson Med. 1994; 32(3):335-41. DOI: 10.1002/mrm.1910320309. View